Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PIRS | Series F Preferred Stock, par value $0.001 per share | Purchase | $1.00 | +1 | $1.00* | 1 | Aug 7, 2024 | Direct | F1 |
Id | Content |
---|---|
F1 | On August 7, 2024, the Reporting Person purchased one (1) share of Series F Preferred Stock, par value $0.001 per share (the "Preferred Stock"), of Pieris Pharmaceuticals, Inc. (the "Issuer") from the Issuer for cash consideration of $1.00. The Preferred Stock has the rights, preferences, privileges and restrictions set forth in the Certificate of Designation of Series F Preferred Stock filed by the Issuer with the Nevada Secretary of State on August 7, 2024 (the "Series F COD"), including the right to have 25,000,000 votes and to vote together with the outstanding shares of the Issuer's common stock as a single class exclusively with respect to such voting proposals defined in the Series F COD. |